Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Pain, Urinary Stone, Urinary Calculi
Interventions: Ketorolac, normal saline; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Status Asthmaticus
Interventions: Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC), Airlife Sidestream High Efficiency Nebulizer; Device
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 12 Months to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions: Levosimendan, Matching Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 16
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more

Conditions: Delirium
Interventions: Ketamine (0.5 mg/kg), Normal Saline (placebo), Ketamine (1 mg/kg); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
Interventions: Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care; Drug
Lead sponsor: APR Applied Pharma Research s.a.; Other
Eligibility: 18 Years to 100 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Fullerton, California • Irvine, California • Miami, Florida + 6 more

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Steroid arm, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine or control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
Interventions: Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate; Procedure · Drug · Combination Product
Lead sponsor: Gary Van Guilder; Other
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Gunnison, Colorado

Conditions: Hypertrophic Scar
Interventions: STP705, Placebo; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Anesthesia, Pain
Interventions: Remifentanil, Normal saline; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 30 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bacterial Infections
Interventions: QPX9003 for IV Infusion, Placebo for IV infusion; Drug
Lead sponsor: Qpex Biopharma, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine, control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 5,715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more

Conditions: Neuropathic Pain
Interventions: KRN5500, Placebo; Drug
Lead sponsor: DARA Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jupiter, Florida + 7 more

Conditions: Pancreas Cancer, Biliary Tract Cancer
Interventions: Alcohol Injection, Placebo Injection; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pain, Chronic Pain, Hyperalgesia
Interventions: Ketamine, Placebos; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Interventions: ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 14
States / cities: Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more

Conditions: Anesthesia
Interventions: AR09 solution, placebo; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: COVID19
Interventions: Tranexamic acid, Placebo oral tablet; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Secondary Osteoporosis, Spinal Cord Injury
Interventions: Denosumab (Prolia), Placebo (normal saline); Drug · Other
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Maximum Tolerated Dose, Dose Escalation
Interventions: AD-NP1, Placebo; Drug
Lead sponsor: Arjun Deb, MD; Other
Eligibility: 21 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Caffeine
Interventions: Caffeine; Drug
Lead sponsor: Sharp HealthCare; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Tibial Meniscus Injuries, Tibial Meniscus Tears, Tibial Meniscus, Torn, Anterior Cruciate Ligament Tear
Interventions: Zilretta, Placebo; Drug · Other
Lead sponsor: Austin V Stone; Other
Eligibility: 18 Years to 40 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Acute Kidney Injury
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 1 Day to 18 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Bone Loss, Aging
Interventions: placebo, denosumab; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 80 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal

Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

Steroid Treatment for Sickle Cell Pain Crisis

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

Near Infrared Spectroscopy Cortical Response to Noxious and Auditory Stimuli in Subjects Under General Anesthesia

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Neuropathic Pain in Patients With Cancer

Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control

Effect of Ketamine on Opioid-Induced Hyperalgesia

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09

Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients

The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

Early Versus Routine Caffeine Administration in Extremely Preterm Neonates

Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury

Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery

Osteoclast Inhibition and Bone Formation